Founded Year



Private Equity | Alive

Total Raised


Last Raised

$10M | 10 mos ago

About Standigm

Standigm is an AI and systems biology-based startup that aims to expedite the drug discovery process. Standigm develops a computer modeling technology that learns medical and biological information and predicts the action mechanism of pharmaceutics in advance. This technology can improve the pharmaceutical development process by tailoring the application of previous know-hows, come up with possible combinations of pharmaceuticals, and optimize the selection of candidates and participants for clinical trials.

Standigm Headquarter Location

3rd Floor 70 Nonhyeon-ro 85-gil, Gangnam-gu

Seoul, 06234,

South Korea


Standigm's Product Videos

ESPs containing Standigm

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare / Biopharmaceuticals

Companies in this market enable virtual trials by testing drugs digitally on simulated versions of living entities. Solutions predict trial outcomes based on a number of different approaches, from using real-world data to simulating human physiology.

Standigm named as Leader among 5 other companies, including GNS Healthcare, Unlearn, and Novadiscovery.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Standigm's Products & Differentiation

See Standigm's products and how their products differentiate from alternatives and competitors

  • Standigm ASK

    Novel target identification AI platform


    Current AI drug discovery is focused on just compound design, and not many AI drug discovery companies have novel target identification AI technology. 

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.


    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Research containing Standigm

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Standigm in 1 CB Insights research brief, most recently on Nov 22, 2019.

Expert Collections containing Standigm

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Standigm is included in 5 Expert Collections, including Clinical Trials Tech.


Clinical Trials Tech

326 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.


Artificial Intelligence

8,694 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Digital Health

12,795 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Clinical Trials Tech Market Map

108 items

This CB Insights Tech Market Map highlights 100+ clinical trials tech companies that are addressing 8 distinct technology priorities that pharmaceutical companies and CROs face.


Biopharma Tech

1,164 items

Standigm Patents

Standigm has filed 2 patents.

The 3 most popular patent topics include:

  • Abandoned drugs
  • Amines
  • Artificial intelligence
patents chart

Application Date

Grant Date


Related Topics



Combination drugs, Abandoned drugs, Amines, Prodrugs, Heat shock proteins


Application Date


Grant Date


Related Topics

Combination drugs, Abandoned drugs, Amines, Prodrugs, Heat shock proteins



Latest Standigm News

DeepMatter soars after signing second multi-year contract

May 11, 2022

A round-up of notable risers and fallers in London on Wednesday DeepMatter Group PLC, the data and software company, surged by 49% to 0.14p after announcing the signing of a second multi-year contract with Standigm. Standigm is a “leading workflow artificial intelligence drug discovery company” based in South Korea, according to a statement. This new agreement is expected to generate revenues of up £280,000, and builds on the first contract that was announced on 1 March. This second agreement with Standigm this year demonstrates our unique portfolio capabilities and also deepens the collaboration between our two businesses,” said Mark Warne, chief executive of DeepMatter. 11.00am: Ilika sinks on higher loss and lower sales Ilika PLC sunk 21% to 74.7p on news of an increased underlying loss and longer than anticipated processes to ensure that product batches can be reproduced to meet exact specifications. It said trading for the year to April has been in line with internal expectations, with the company continuing to explore opportunities for its solid-state batteries. The solid-state battery technology expert revealed revenues are expected to come in at around £0.5mln, with an increased underlying loss of around £7.0mln from the build-out and opening of its manufacturing facility for the Stereax micro batteries. That would represent a 78% reduction in sales compared with the previous year ended 30 April 2021 and a 300% increase in losses. 9.05am: Trafalgar Property goes vertical (farming) with new board appointment   Trafalgar Property Group PLC (AIM:TRAF) shares went vertically higher, jumping 200% to 1.07p, after it announced the appointment of vertical farms expert Paul Challinor as an executive director with immediate effect. A specialist in the construction and management of indoor hydroponic vertical farming facilities, Dr Challinor and with Gary Thorneycroft, Trafalgar's chief financial officer, were co-founders of Jones Food Company (JFC), which was the largest vertical farm in Europe when  a majority stake was bought by Ocado in 2019 . Paul Treadaway, managing director of Trafalgar, said: "We view Paul's appointment as the key step in the development of Trafalgar's long-planned hydroponic division as he is a UK pioneer in this high growth market. "The board believes Paul's appointment which has been in negotiation for some time, will help Trafalgar to re-invigorate its hydroponics strategy. Paul's experience and expertise together with that of Gary Thorneycroft, will greatly assist Trafalgar in realising its aspirations to design, fit out, build and where appropriate even operate hydroponic assets."

Standigm Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Standigm Rank

You May Also Like

GNS Healthcare Logo
GNS Healthcare

GNS Healthcare applies artificial intelligence (AI) platform to unravel the complexity of human disease in order to match the right treatment to the right patient at the right time.

Insilico Medicine Logo
Insilico Medicine

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong developing a range of generative adversarial networks (GANs) and reinforcement learning approaches to identify protein targets, generate molecular structures with specified properties and generate synthetic data.

Cyclica Logo

Cyclica is a global biotechnology company that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. Cyclica's structure-based and AI-augmented drug discovery platform includes Ligand Design for multi-targeted and multi-objective drug design, and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights.


BERG is a Boston-based biopharma company focused on taking a bold "back to biology" approach to therapeutic discovery using its unique AI-based Interrogative Biology platform. This platform combines patient biology and artificial intelligence-based analytics to engage the differences between healthy and disease environments. The patient's own biology drives the platform's results and guides the company in the discovery and development of drugs, diagnostics and healthcare applications. Its platform utilizes patient population health data to bring actionable Patient Intelligence to precision medicine applications. This means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems.

Atomwise Logo

Atomwise uses deep learning neural networks to help discover new medicines. Atomwise achieves results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID.

Healx Logo

Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Its AI drug discovery platform leverages public and proprietary biomedical data and features a knowledge graph for rare diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.